Introduction
plant patients. This text tries to clarify the definitions used to assess quality of life. We shall then proceed to Quality of life has emerged as an important outcome elaborate on the importance of assessing side-effects of measure in health care over the past two decades and immunosuppressive regimens in transplanted patients is increasingly used to evaluate treatment options.
within a quality-of-life framework. Indeed, understanding the quality-of-life implications of a new treatment modality in addition to studying its effects in terms of incidence of complications and Definition of quality of life mortality rate provides a more sophisticated and balanced view of treatment effects. Quality-of-life data Although quality of life is increasingly assessed in offer a more complete understanding of the benefit/ research and clinical practice, no consensus exists burden ratio associated with medical treatments in concerning the definition or the measurement of this view of patients' physical, emotional/mental and social multidimensional concept. Quality of life can include functioning. Furthermore, it provides a significant con-a number of dimensions that refer to physical, psychotribution to the allocation of health care resources, in logical, mental, emotional, social, spiritual, and vocadetermining reimbursement policies, and in individual tional function [3, 4] . Though some of these dimensions medical decision processes [1, 2] . may be relevant to understanding specific human Although quality of life has been extensively studied responses to a particular treatment option (e.g. spiritual in transplant patients, a systematic assessment of symp-beliefs), they are not necessarily regarded as pertinent toms and of side-effects related to immunosuppressive to medical and health services research. drugs is rarely integrated into quality-of-life research.
Based on the WHO definition of health, defined as However, the patient's appraisal of side-effects of 'a state of complete physical, mental and social wellimmunosuppressive drugs is of utmost importance to being and not merely absence of disease or infirmity' of life that is traditionally measured in clinical trials and medical research to evaluate the benefit/burden Conceptualization of transplant patients' symptom experience ratio of new treatment modalities.
Testa and Simonson's [6 ] conceptual scheme of the Symptom experience consists of two different, although domains and variables involved in quality of life pro-linked concepts, i.e. symptom occurrence and symptom vides a useful framework in unravelling the different distress [7] . Symptom occurrence, the cognitive comcomponents of health-related quality of life. This model ponent of symptom experience, can be measured along operationalizes health-related quality of life based on the dimensions of frequency, severity, and duration of the physical, psychological and social domains of symptoms. Symptom distress refers to the mental health. Each of these domains comprises an objective anguish or suffering caused by the symptom and is the as well as a subjective dimension. The objective dimen-emotional component of symptom experience [7] . sion reflects the health status of a patient based on an Previous research in transplant recipients showed that objective evaluation of his/her functioning. The sub-the most frequent side-effects of immunosuppressive jective dimension reflects the patients' perceptions of drugs are not necessarily the most distressing ones, their physical, psychological and social functioning. and vice versa [8, 9] . Both dimensions are relevant in that they contribute to a better understanding of the patients' overall
Relevance of symptom experience for transplant health-related quality of life [6 ] .
research and clinical management Each of the three health domains can be further operationalized. The physical domain encompasses for For several reasons the transplanted patient's symptom instance ambulation, mobility, fatigue, pain, sleep, and experience, i.e. symptom occurrence and symptom ability to perform daily activities. Depression, anxiety, distress, are parameters that are relevant both for emotional well-being, and cognitive status fall within transplant research and for clinical management. First, the mental/cognitive domain. The social domain of higher levels of symptom distress are associated with health-related quality of life includes, for example, lower perceived overall quality of life [6, [10] [11] [12] . work status, role functioning, personal relationships, Second, symptom distress may trigger non-compliance and sexual functioning [6 ] . Again, each variable can with the immunosuppressive regimen [13] . For instance be assessed from a subjective and an objective a young female transplant recipient may stop taking perspective.
immunosuppressive medication, because the cosmetic side-effects are extremely disturbing (changed facial and body appearance, i.e. moon face, buffalo hump and increased hair growth). Third, information concerning the transplanted patient's symptom experience
Patients' appraisal of side-effects in quality-of-life
can be used for pre-and post-transplant education to assessments in transplant recipients complement information about the 'traditional' sideeffects of immunosuppressive drugs. Traditionally, side-effects of immunosuppressive regimens have been evaluated based upon their impact on Measurement of symptom experience morbidity and mortality. Indeed, the occurrence of nephrotoxicity, hypertension, malignancies, osteopor-The first instrument assessing the patient's symptom osis, and diabetes are closely monitored during the experience associated with immunosuppressive regimen post-transplant course as they may negatively affect was the Transplant Symptom Frequency and Distress the transplant recipient's clinical outcome. Going back Scale [10, 11] . This 27-item instrument was developed to , in the early 1980s and measured the symptom frehealth-care workers have traditionally relied upon quency (only one dimension of symptom occurrence) objective criteria as the primary means of evaluating and symptom distress associated with side-effects treatment side-effects. While the objective component of triple therapy (i.e. cyclosporin, azathioprine, and of quality of life has been well documented and integ-corticosteroids). Our research group performed consecrated within clinical transplant practice, the subjective utive adaptations of Lough's instrument [10, 11] , component is less well understood.
resulting in the 'Modified Transplant Symptom The transplanted patient's subjective appraisal of Occurrence and Symptom Distress Scale' that measures side-effects and of the perceived associated distress is the transplanted patient's symptom experience. a key to understanding the balance between benefit Adaptations were based on a comprehensive literature and burden of immunosuppressive regimens after review of side-effects of immunosuppressive drugs, on transplantation. Some side-effects (e.g. impotence, our previous research on symptom experience associmuscular weakness, gingival hyperplasia) have little or ated with these side-effects [8, 9] , as well as by expert no direct effect on morbidity and mortality, yet can be review. The last version of the instrument includes 45 perceived by transplanted patients as extremely dis-symptoms related to side-effects of tacrolimus, cycloturbing. Assessing the transplant recipient's subjective sporin, corticosteroids, azathioprine, and MMF. The experience of symptoms associated with his/her items are scored on a 5-point rating scale ranging from immunosuppressive regimen falls within the subjective 0 (never occurring) to 4 (always occurring) for symptom occurrence and from 0 (not distressing at all ) to domain of quality of life assessment. 
